These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7765373)

  • 21. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
    Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
    Thromb Haemost; 1992 Dec; 68(6):672-7. PubMed ID: 1287881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and secretion of a fibrinolytically active tissue-type plasminogen activator variant in Escherichia coli.
    Waldenström M; Holmgren E; Attersand A; Kalderén C; Löwenadler B; Rådén B; Hansson L; Pohl G
    Gene; 1991 Mar; 99(2):243-8. PubMed ID: 1902433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain.
    Parcq J; Bertrand T; Baron AF; Hommet Y; Anglès-Cano E; Vivien D
    J Thromb Haemost; 2013 Mar; 11(3):539-46. PubMed ID: 23301636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autonomous functions of structural domains on human tissue-type plasminogen activator.
    van Zonneveld AJ; Veerman H; Pannekoek H
    Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4670-4. PubMed ID: 3088564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
    Emeis JJ; Verheijen JH
    Arzneimittelforschung; 1992 Mar; 42(3):358-62. PubMed ID: 1497699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of recombinant proteins: biochemical and biophysical criteria for the identity of native and renatured human tissue plasminogen activator and its mutants.
    Vogl T; Hinz HJ
    Biotechnol Appl Biochem; 1994 Aug; 20(1):1-22. PubMed ID: 7917059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urokinase mutant with better fibrin-specificity.
    Ma Z; Yu R; Hua Z; Zhu D
    Sci China C Life Sci; 1996 Oct; 39(5):523-33. PubMed ID: 9772355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator.
    Silva MM; Thelwell C; Williams SC; Longstaff C
    J Thromb Haemost; 2012 Nov; 10(11):2354-60. PubMed ID: 22974122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression, purification and characterization of recombinant plasminogen activator from Gloydius brevicaudus venom in Escherichia coli.
    Zhang J; Meng W; Wang C; Wu Z; Wu G; Xu Y
    Protein Expr Purif; 2013 Sep; 91(1):85-90. PubMed ID: 23891573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble expression of active recombinant human tissue plasminogen activator derivative (K2S) in Escherichia coli.
    Luo XG; Tian WJ; Ni M; Jing XL; Lv LH; Wang N; Jiang Y; Zhang TC
    Pharm Biol; 2011 Jun; 49(6):653-7. PubMed ID: 21554008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.
    Smalling RW
    Eur Heart J; 1997 Dec; 18 Suppl F():F11-6. PubMed ID: 9447335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli.
    Manosroi J; Tayapiwatana C; Götz F; Werner RG; Manosroi A
    Appl Environ Microbiol; 2001 Jun; 67(6):2657-64. PubMed ID: 11375177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of a novel chimeric tissue plasminogen activator with favorable Vampire bat plasminogen activator properties.
    Kazemali M; Majidzadeh-A K; Sardari S; Saadatirad AH; Khalaj V; Zarei N; Barkhordari F; Adeli A; Mahboudi F
    Enzyme Microb Technol; 2014 Dec; 67():82-6. PubMed ID: 25442953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2.
    Carroll VA; Nikitenko LL; Bicknell R; Harris AL
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):736-41. PubMed ID: 15692103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implication of cysteine residues in the activity of single-chain urokinase-plasminogen activator.
    Hamelin J; Sarmientos P; Orsini G; Galibert F
    Biochem Biophys Res Commun; 1993 Jul; 194(2):978-85. PubMed ID: 8343178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model.
    Matsuno H; Uematsu T; Nakashima M
    Br J Pharmacol; 1993 Dec; 110(4):1278-9. PubMed ID: 8306063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin.
    Verheijen JH; Caspers MP; Chang GT; de Munk GA; Pouwels PH; Enger-Valk BE
    EMBO J; 1986 Dec; 5(13):3525-30. PubMed ID: 3030730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrin affinity and clearance of t-PA deletion and substitution analogues.
    Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E
    Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.